TRILEPTAL
LOE ApproachingNDAORALSUSPENSION
Approved
May 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 3h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRILEPTAL (oxcarbazepine) is an oral anti-epileptic agent approved in 2001 for seizure management. It is a small-molecule anticonvulsant available in suspension formulation. The drug is used as monotherapy or adjunctive therapy in patients with partial seizures.
$21MPart D
LOE Approaching2% of anti-epileptic market
With LOE approaching and modest spending of $21M annually, commercial teams should expect modest headcount and focus shifting toward generic transition management and cost containment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Careers on TRILEPTAL involve defending market share in a highly competitive anti-epileptic category while preparing for near-term generic entry. This role emphasizes relationship management, contracting acumen, and operational efficiency rather than innovation—suitable for professionals seeking to master mature product commercialization and managed market dynamics.
Brand Manager
Worked on TRILEPTAL at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.